RT Journal Article
SR Electronic
T1 The central nervous system’s proteogenomic and spatial imprint upon systemic viral infections with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.16.22283804
DO 10.1101/2023.01.16.22283804
A1 Radke, Josefine
A1 Meinhardt, Jenny
A1 Aschman, Tom
A1 Chua, Robert Lorenz
A1 Farztdinov, Vadim
A1 Lukkassen, Sören
A1 Ten, Foo Wei
A1 Friebel, Ekaterina
A1 Ishaque, Naveed
A1 Franz, Jonas
A1 Huhle, Valerie Helena
A1 Mothes, Ronja
A1 Peters, Kristin
A1 Thomas, Carolina
A1 Streit, Simon
A1 Manitius, Regina von
A1 Körtvélyessy, Péter
A1 Vielhaber, Stefan
A1 Reinhold, Dirk
A1 Hauser, Anja
A1 Osterloh, Anja
A1 Enghard, Philipp
A1 Ihlow, Jana
A1 Elezkurtaj, Sefer
A1 Horst, David
A1 Kurth, Florian
A1 Müller, Marcel A.
A1 Gassen, Nils C.
A1 Schneider, Julia
A1 Jechow, Katharina
A1 Timmermann, Bernd
A1 Fernandez-Zapata, Camila
A1 Böttcher, Chotima
A1 Stenzel, Werner
A1 Wyler, Emanuel
A1 Corman, Victor
A1 Stadelmann-Nessler, Christine
A1 Ralser, Markus
A1 Eils, Roland
A1 Heppner, Frank L.
A1 Mülleder, Michael
A1 Conrad, Christian
A1 Radbruch, Helena
YR 2023
UL http://medrxiv.org/content/early/2023/01/18/2023.01.16.22283804.abstract
AB In COVID-19 neurological alterations are noticed during the systemic viral infection. Various pathophysiological mechanisms on the central nervous system (CNS) have been suggested in the past two years, including the viral neurotropism hypothesis. Nevertheless, neurological complications can also occur independent of neurotropism and at different stages of the disease and may be persistent.Previous autopsy studies of the CNS from patients with severe COVID-19 show infiltration of macrophages and T lymphocytes, especially in the perivascular regions as well as pronounced microglial activation, but without signs of viral encephalitis.However, there is an ongoing debate about long-term changes and cytotoxic effects in the CNS due to the systemic inflammation.Here, we show the brain-specific host response during and after COVID-19. We profile single-nucleus transcriptomes and proteomes of brainstem tissue from deceased COVID-19 patients who underwent rapid autopsy. We detect a disease phase-dependent inflammatory type-I interferon response in acute COVID-19 cases. Integrating single-nucleus RNA sequencing and spatial transcriptomics, we could localize two patterns of reaction to severe systemic inflammation. One neuronal with direct focus on cranial nerve nuclei and one diffusely affecting the whole brainstem, the latter reflecting a bystander effect that spreads throughout the vascular unit and alters the transcriptional state of oligodendrocytes, microglia and astrocytes.Our results indicate that even without persistence of SARS-CoV-2 in the CNS, the tissue activates highly protective mechanisms, which also cause functional disturbances that may explain the neurological symptoms of COVID-19, triggered by strong systemic type-I IFN signatures in the periphery.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germanys Excellence Strategy EXC-2049-390688087, as well as SFB TRR 167 and HE 3130/6-1 to F.L.H., CRC130 P17 to H.R. and A.E.H., HA 5354/10-1 to A.E.H. and RA 2491/1-1 to H.R.; by the German Center for Neurodegenerative Diseases (DZNE) Berlin, by the European Union (PHAGO, 115976; Innovative Medicines Initiative-2; FP7-PEOPLE-2012-ITN: NeuroKine) and by the Ministry for Science and Education of Lower Saxony through the program Niedersachsisches Vorab to J.F.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics commitee of Charite Universitymedicine Berlin Chariteplatz 1, 10117 Berlin (Germany) gave ethical approval for this study under the following registration numbers: EA1/144/13, EA2/066/20, EA1/075/19 and EA1/076/20.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.